Evidence map›Paper›PMID 39300544›Full record

ArticleBMC chemistry2024

Bridging one health and sustainable analysis: enrofloxacin quantification amid combined therapy and its active metabolite in various matrices using green RP-HPLC.

Heba M Mohamed, Mona T Ragab

Abstract read
In one paragraph

Article in BMC chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Heba M MohamedAnalytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, 11562, Egypt. heba.moustafa@pharma.cu.edu.eg.
Mona T RagabAnalytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, 11562, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibiotics play a crucial role in the treatment of infectious diseases in both humans and animals. However, their extensive utilization has caused significant potential harm to both wildlife and humans. Enrofloxacin (ENR) is a common veterinary antibiotic, which is not approved for human use due to associated toxicities. It is often combined with other antibiotics to expand the antibacterial range. It is crucial to monitor and measure the levels of ENR medication in various matrices. RP-HPLC is highly effective for analyzing antibiotics due to its sensitivity, specificity, and ability to handle complex samples. By adopting eco-friendly solvents, decreasing solvent consumption, and limiting waste we developed a method for determination and quantification of ENR, amoxicillin (AMX), and ENR active metabolite in different matrices. The method utilized a reversed stationary phase and a mobile phase composed of phosphate buffer pH 3.0: ethanol (90:10 v/v) pumped at 1.0 mL/min and UV detection at 254.0 nm. Moreover, a comprehensive assessment of the environmental friendliness of the established method was conducted using various tools including the Green Certificate Classification (GCC) and Analytical Greenness AGREE and RGB12. The method was validated for its accuracy and precision in quantifying ENR, demonstrating its potential for the effective monitoring of ENR and contributing to public health protection.

Indexed as

Antibiotics analysisEnrofloxacinGreen analysisGreenness assessmentPharmaceutical and biological samples

Identifiers

PMID39300544
PMCPMC11414176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.